The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length ...

A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.

PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...

Mural Oncology a clinical-stage oncology company focused on discovering and developing immunotherapies, held its first ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Erasca has streamlined its pipeline, now focusing on a phase 3 trial for Naporafenib targeting NRAS-mutant melanoma. Read ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Dr. Gopakumar Iyer discussed how to Integrate Novel Therapeutics with trimodal therapy (TMT). Radiation therapy (RT) has ...

Improved disease-free survival seen among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery.